A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
New therapies including CAR-T, bispecific antibodies and dual-antibody immunotherapy are reshaping multiple myeloma care. Advances in genomic testing may also improve risk assessment and treatment decisions.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
A CNIC study demonstrates that remote ischemic conditioning can protect the heart during anthracycline chemotherapy without compromising antitumor efficacy, while researchers explore additional methods to manage chemotherapy side effects.
The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Orca-T, an investigational T-cell therapy under FDA priority review, is being studied to reduce graft-versus-host disease in patients undergoing allogeneic stem cell transplant for acute leukemias and high-risk blood disorders, with a decision expected in April 2026.
Zenyaku Kogyo obtained Japanese regulatory approval for Rituxan (rituximab) as a treatment for autoimmune hemolytic anemia, a government-designated intractable disease. The approval follows a public knowledge-based application submitted in August 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07603128 |
Multicenter Validation of a Risk Prediction Model for MDRGNB Infection |
NOT_YET_RECRUITING | |
| NCT07575009 |
Continuous Antibiotic Infusion In Children |
RECRUITING | PHASE3 |
| NCT07556107 |
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07536035 |
Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness |
RECRUITING | |
| NCT07511881 |
Far-UVC and Infections in Long-term Care Facilities |
COMPLETED | NA |
| NCT07493798 |
Serum Potassium Prediction Using Machine Learning and Single-lead ECG |
WITHDRAWN | |
| NCT07484633 |
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07471542 |
Copper Supplementation in Cirrhosis |
RECRUITING | NA |
| NCT07458763 |
Rapid Response Home Care as an Alternative to Acute Admission |
ACTIVE_NOT_RECRUITING | NA |
| NCT07397689 |
Early Sepsis Recognition Tool |
NOT_YET_RECRUITING |
